Innovations for Heart and Vesselssp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Innovations for Heart and Vessels develops InFlow transcatheter aortic valves for TAVI, using biological porcine tissue or biocompatible polymers. The valves offer high biocompatibility, a low risk of calcification and enhanced durability through a proprietary component-joining method, supported by an atraumatic self-positioning delivery system.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Publication: Long-term Bio-functional Performance of a Novel, Self-positioning Balloon Expandable Transcatheter Biological Aortic Valve System in the Ovine Aortic Banding Model – Cardiology Journal, 2
Presentation: Innovations for Heart and Vessels – Introduction to the InFlow Project
Video: InFlow TAVI Project – Brief Presentation
Publication: Biomechanical Evaluation of a Novel Polymeric Aortic Valve
Presentation: Innovative Polymeric TAVI Valve System InFlow – TCT 2022
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-07-23. Active
11 1600 1462 1717 7107 8000 0007- 49 1600 1462 1717 7107 8000 0002
- 65 1600 1462 1717 7107 8000 0005
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
10 public aid cases recorded, with a total value of $17,784,105.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 14, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $7,563$7,563 | Akademia Śląska | |
| Jun 27, 2025 | Aid for research and development projects: experimental development | $6.2M$6,216,954 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Jun 27, 2025 | Regional investment aid | $1.3M$1,268,747 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $18,149,567.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-11-04 | Opracowanie technologii produkcji oraz prototypów polimerowych implantów zastawkowych do przezskórnego i małoinwazyjnego leczenia wad zastawkowych | $7.5M$7,468,820 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-05-01 | Opracowanie technologii produkcji oraz prototypów biologicznych implantów zastawkowych do przezskórnego i małoinwazyjnego leczenia wad zastawkowych. | $8.0M$7,987,607 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-03-01 | Polimerowe przezcewnikowe implanty zastawki aortalnej wraz z dedykowanym systemem wprowadzającym | $2.7M$2,678,785 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, declarations of will, signing documents on behalf of the company and granting powers of attorney require the joint action of two members of the management board, including in every case the President of the Management Board, if appointed, and in the case of a one-person management board, the company is represented independently by the President of the Management Board.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Paweł Eugeniusz Buszman (65) | 268 | $7,239.33 | 40.8537% |
Fundacja Rodzinna Pro Benefis Familiae | 195 | $5,267.42 | 29.7256% |
Others | 193 | $5,213.40 | 29.4207% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Paweł Eugeniusz Buszman (65)  | Shareholder of a limited liability company, 26800.0 PLN | |
Piotr Paweł Buszman (42) | Beneficjent fundacji rodzinnej pro benefis familiae z siedzibą w katowicach (40-748), ul. nagietek 9, będącej wspólnikiem spółki | |
Zofia Buszman (66) | Beneficjent oraz fundator fundacji rodzinnej pro benefis familiae z siedziba w katowicach (40-748), ul. nagietek 9, będacej wspólnikiem spółki | |
Zuzanna Zofia Buszman (31) | Beneficjent fundacji rodzinnej pro benefis familiae z siedzibą w katowicach (40-748), ul. nagietek 9, będącej wspólnikiem fundacji |
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Graftflowsp. z o.o. | 1,269.58 USD | 63.0872% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiottsS.A. | $372,115.60 | biotts.com | ||
| Quantum Innovationssp. z o.o. | $167,489.61 | quantuminnovations.pl | ||
| SimplicardiacS.A. | $28,951.71 | simplicardiac.com | ||
| ArthecS.A. | $10,911.16 | arthec.eu |
Change history
| Date | Event | |
|---|---|---|
| 2024-06-13 | Share capital change (44,500.00 PLN → 65,600.00 PLN) | |
| 2024-02-15 | Share capital change (44,000.00 PLN → 44,500.00 PLN) | |
| 2023-06-02 | Share capital change (42,700.00 PLN → 44,000.00 PLN) | |
| 2022-04-08 | Share capital change (40,000.00 PLN → 42,700.00 PLN) | |
| 2022-02-18 | PKD change (Removed: 18.20.Z, 32.99.Z, 35.11.Z, 35.12.Z, 35.13.Z, 35.14.Z, 36.00.Z, 38.11.Z, 68.10.Z, 68.20.Z, 72.20.Z, 82.11.Z, 82.19.Z, 82.30.Z, 82.99.Z, 85.59.B, 85.60.Z, 96.09.Z) |
FAQ
Last updated: 2026-06-24